Contact
searchSearch
HMP Global
Login
Quiz

Why should anticholinergics be avoided in TD?

Edited by 
Maria Mantas
04/17/2026

Related Content

Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use